• Damora outlined a mutCALR-focused pipeline for myeloproliferative neoplasms, targeting essential thrombocythemia and myelofibrosis.
• Lead antibody DMR-001 entered Phase 1/1b CLARITY-101, with two proof-of-concept readouts expected beginning mid-2027.
• Damora reported about $541 million in cash to fund DMR-001 through proof-of-concept and into registrational development.
• DMR-002, an Fc-enhanced anti-mutCALR antibody, is slated for a first regulatory submission in 2H 2026; DMR-003 targeted in 2027.
• The deck pegged the US mutCALR-driven MPN opportunity at more than $5 billion, citing roughly 42,000 prevalent patients across ET and MF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.